USA Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining in January. With an ambition to build a 1 billion USD global business (the US is expected to drive more…
Global Affordability and innovation are usually framed as a zero-sum trade-off in drug pricing debates. Zeba M. Khan, editor-in-chief of ISPOR’s Value & Outcomes Spotlight magazine, makes the case that they don’t have to be — if pricing policy is grounded in evidence rather than blunt instruments. Khan walks through the…
Europe The EU Health Technology Assessment Regulation was implemented in January 2025 to replace 27 fragmented national evaluations with a single Joint Clinical Assessment, run in parallel with EMA review. The idea was simple enough and aimed at giving European patients faster, more equitable access to innovative medicines. In practice, the…
USA Pamela Hoffman is the president and recently appointed CEO of Padagis, a US-based generic pharmaceutical company established following the divestiture of Perrigo’s generics business. With manufacturing operations in Minnesota and Israel and a portfolio of over 330 SKUs, Padagis has built its reputation as a market leader in generic extended…
Germany Germany’s research-based pharmaceutical industry is approaching a defining period as mounting pressure to curb healthcare expenditure clashes with the country’s long-established ambition to remain a leading hub for innovation, scientific research, and advanced manufacturing. Han Steutel, President of the vfa, cautions that although Germany continues to benefit from world-class scientific…
Europe Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly shaped by the US and China. In this conversation, Iris Zemzoum discusses Europe’s readiness for next-generation therapies such as radioligand…
Global Brendan Shaw maps the global fallout from the Trump Administration’s Most Favoured Nation drug pricing agenda. From stalled launches to rattled health ministries, Shaw argues that MFN has thrown pharmaceutical pricing strategy into unprecedented chaos while uncovering a counterintuitive silver lining for access in low- and middle-income countries. In a…
Europe Europe’s long-anticipated shift to a unified Health Technology Assessment framework is no longer theoretical, it is now being tested in practice. As the results from the first Joint Clinical Assessments begin to emerge, Niklas Hedberg describes a system balancing ambition with reality, aligning 27 Member States while managing expectations from…
Europe As Europe rethinks how medicines are priced, regulated, and manufactured, the off-patent sector is moving to the centre of the policy debate. Adrian van den Hoven, Director General of Medicines for Europe, examines the pressures shaping the market, from supply resilience and environmental rules to biosimilars, trade tensions, and the…
USA Successive American governments have grappled with the need to contain spiraling healthcare costs while sustaining the USA’s well-earned reputation as the number one launch market for breakthrough medical innovations. “The most difficult question of our time in our sector relates to how to fund access to advanced therapies,” explains Marwan…
USA Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by patients in the US having more innovative medicines available to them than anywhere else on earth, but the market’s long-criticized…
Europe Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and…
See our Cookie Privacy Policy Here
